AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04878016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide (100 mg/m\^2) should be administered intravenously over 60 minutes following carboplatin administration. On Days 2 and 3 of each cycle, etoposide 100 mg/m2) should be administered intravenously over 60 minutes.~Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy.
Study NCT04878016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide
Description: Etoposide (100 mg/m\^2) should be administered intravenously over 60 minutes following carboplatin administration. On Days 2 and 3 of each cycle, etoposide 100 mg/m2) should be administered intravenously over 60 minutes.~Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy.
Study NCT03976895 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Supine position (SP)
Description: Infants under high flow nasal cannula (HFNC) will be positioned in the supine position.~Patients may be positioned temporarily in lateral position between periods of supine position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis.
Study NCT03976895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone position (PP)
Description: Infants under high flow nasal cannula (HFNC) will be placed in the prone position during at least 24 hours over the first 48 hours. The positioning will be standardized (chest on the bed plan and abdomen cleared) and children should be placed in the prone position immediately after randomization.~Patients may be positioned temporarily in lateral position between periods of prone position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis.
Study NCT05404867 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fMRI
Description: fMRI scan for 1 hour
Study NCT05307016 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Two dimensional ultrasonography power and color doppler
Description: transabdominal and transvaginal two-dimensional power Doppler ultrasound volumes of the placental bed were obtained according to a predefined protocol with the participant in a semi-recumbent position and a full bladder using a RAB4-8-D 3D/4D curved array abdominal transducer (4-8.5 MHz) on a Voluson E8. Predetermined machine settings were used. To allow for differences in attenuation of the power Doppler signal resulting from variation in placental site and maternal adiposity.~Intraoperative staging of degree of placental invasion will be done according to clinical grading system by Collins et al., 2015.~Specimens obtained from patients who underwent hysterectomy or resection of segment of anterior uterine wall in cases with anterior placenta previa will be immersed in formalin 10% concentration and will be sent for histopathological evaluation that will be done by the same pathologist.
Study NCT06105749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: contrast-enhanced mammography
Description: Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to increased and leaky blood vessels. Contrast-enhanced mammography is used as an adjunct following mammography and/or ultrasound examinations to localize a known or suspected lesion.
Study NCT05784974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: 15 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
Study NCT05545631 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention in this study
Study NCT05030194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: Participants engage in 30 minutes of an oral nicotine product. In those 30 minutes the product can be used as much or as little as preferred.
Study NCT05030194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Nicotine Pouch
Description: Participants will be instructed to place a 6mg nicotine pouch in their mouth between gum and lip for up to 30 minutes.
Study NCT06004609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Description: Low-level laser therapy (LLLT), three time each week, 10 minutes each time, during the first 8 weeks of the treatment trial.
Study NCT06004609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Conventional physical therapy will be applied three time each week, for 12 weeks
Study NCT06004609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: Conventional physical therapy will be applied three time each week, for 12 weeks
Study NCT05487456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P4M3 CA35
Description: Ad libitum use of P4M3 with CA35 cartridges
Study NCT05487456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P4M3 CM35
Description: Ad libitum use of P4M3 with CM35 cartridges
Study NCT05487456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CIG
Description: Ad libitum use of subject's own preferred brand of cigarettes
Study NCT05487456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Abstinence
Description: Abstention from cigarette smoking
Study NCT05115422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'Coping with Brain Fog' program
Description: The proposed intervention is an 8-week 'Coping with Brain Fog' program for cancer survivors, adapted for AYAs with cancer, with one 90-minute group session per week. The intended group size for the program is 8-12 participants. The program was developed to be delivered in person, however for the purposes of this study it will be conducted in a virtual setting. The overall goals of the program are to educate participants about cancer-related brain fog and enhance their cognitive function and wellbeing. To accomplish this, the program is segmented into three main components: memory skills, task management, and psychological wellbeing. For each component, participants are systematically introduced to evidence-based strategies to cumulatively build a repertoire of cognitive tools designed to reduce the impact of cancer-related brain fog. The program uses a manual and participant materials that are copyrighted by Maximum Capacity Inc.
Study NCT05753891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suture Tape Reconstruction
Description: This intervention will utilize a suture tape to suspend the 1st and 2nd metacarpal post trapeziectomy compared to the standard procedure of a trapeziectomy followed by ligament reconstruction and tendon interposition.
Study NCT06179017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group:Intervention Group
Description: Intervention Group:Interventionist choose the optimal endovascular treatment (EVT) strategy and device based on the patient's condition and local guidelines. The patient will receive the best medical treatment according to the local guidelines.
Study NCT06179017 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group:best medical treatment
Description: Best medical treatment:Patients will receive the best medical treatment according to local guidelines, including antiplatelet agents, anticoagulants, thrombolysis, etc., but not any EVT. In the control arm, rescue EVT is allowed in patients with disease progression leading to an increase in NIHSS≥4 and excluding the impact of non-stroke factors, and the onset-to-treatment time is within 24 hours.
Study NCT05466968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suxiao Jiuxin Pills
Description: Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
Study NCT05466968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The placebo of Suxiao Jiuxin Pills
Description: The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
Study NCT04980755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Reprogramming
Description: An educational intervention originally designed for patients with fibromyalgia.
Study NCT04906707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EaseVRx
Description: EaseVRx is a commercially available pain management program. It is a multi-modal, skills-based, 8-week, VR, mind-body approach to daily management of chronic pain that is designed for home use to be worn over the eyes. The program contains five types of modules that are as follows: Interoception, Education, 360-degree relaxation videos, Games, and Dynamic breathing. All program content is mapped to a therapeutically designed curriculum with weekly themes. The following core themes are infused into the curriculum: Acceptance, Attention shifting, Awareness, Rehabilitation, Self-compassion, Healthy Movement, Deep relaxation, Visualization, Knowledge of pain, Distraction, and Immersive enjoyment.
Study NCT04906707 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audio-only version of EaseVRx
Description: Participants in the control group will be asked to use the audio-only version of EaseVRx, which excludes references to visual content, to complete 7 sessions weekly. They will receive an electronic link to the recordings on SoundCloud (a music streaming platform) where they can choose to stream or download the audio recordings on their smartphone, laptop, or desktop computer.
Study NCT05501015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice chips
Description: Consuming small amounts of ice chips with supervision
Study NCT04827966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinpro® 5% sodium fluoride plus tri calcium phosphate varnish
Description: Clinpro® is 5% sodium fluoride varnish and is indicated to be used for hypersensitive as well as for demineralized teeth. It flows smoothly on moist teeth and binds firmly to their surfaces. 1ml of Clinpro® contain 50 mg of sodium fluoride
Study NCT04827966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tooth Mousse® - Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP)s
Description: Tooth Mousse® contains Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP) is product from the milk casein. This delivers the necessary Calcium and Phosphate ions to the tooth, which will reduce the risk of caries and white spot by enhancing tooth remineralization.
Study NCT04827966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MI Paste® -Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF)
Description: MI Paste® which is Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF) additional contains fluoride in addition to CPP-ACP. The level of fluoride is 900ppm which approximates that in adult strength toothpastes.
Study NCT04827966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zap® 1.23% APF gel - Acidulated phosphate fluoride
Description: 1.23% APF (Acidulated phosphate fluoride) gel is routinely used professional based fluoride for patients with high caries risk.
Study NCT04827966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Listerine fluoride mouthrinse
Description: Listerine® Sodium fluoride (0.2%) mouth rinses are effective in reducing caries and inhibit carbohydrate utilization of oral microorganisms by blocking enzymes involved in the bacterial glycolytic pathway studies have shown sodium fluoride mouth rinse to be effective in reducing S. mutans counts
Study NCT06181305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate and letrozole
Description: hormone replacement therapy by estradiol valerate plus letrozole incorporation .
Study NCT06181305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole 2,5 mg tablet
Description: mild ovarian stimulation
Study NCT05400733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Total Amino Acids
Description: Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Alanine, Arginine, Aspartate, Cystine, Glutamine, Glutamate, Glycine, Proline, Serine, Tyrosine. All supplements are commercially available.
Study NCT05400733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Essential Amino Acids
Description: Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine. All supplements are commercially available.
Study NCT05400733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Essential Amino Acids + Hydroxy-methylbutyric acid (HMB)
Description: Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, HMB. All supplements are commercially available.
Study NCT05400733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Essential Amino Acids + Leucine
Description: Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Extra leucine. All supplements are commercially available.
Study NCT05400733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Essential Amino Acids High
Description: Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine. All supplements are commercially available.
Study NCT05400733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo Water
Description: Water
Study NCT05668143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The Patient Information Form and the State Anxiety Scale will be administered to the patients just before the surgery. The researcher will measure the patient's respiratory, blood pressure, pulse and oxygen saturation values on the monitor just before the start of the operation and every 15 minutes after the operation, and the vital signs will be recorded in the follow-up form. Virtual reality glasses will be put on the patient immediately after anesthesia is given to the patient by the anesthesiologist. Glasses will be worn during the total knee replacement surgery. Total knee replacement surgery takes an average of 60 minutes. During the surgery, patients will be shown nature and landscape images with virtual reality glasses. Virtual reality glasses will be removed immediately after the operation and the State Anxiety Scale and vital signs follow-up form will be applied before the patient is sent to the service from the operating room.
Study NCT03825835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% oxygen group
Description: Infants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed.
Study NCT04930328 — intervention group
Intervention type: DRUG
Intervention: Oxbryta® (voxelotor) 500-mg Tablets
Description: Patients will have received treatment with Oxbryta as prescribed by their physician at the approved dose per local prescribing information, as part of their usual care.
Study NCT03825835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60% oxygen group
Description: Infants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed.
Study NCT05144503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpherePVI™ Catheter
Description: SpherePVI™ Catheter with the Affera Mapping and Ablation System
Study NCT05798741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hardware removal
Description: The surgery of hardware removal after an ORIF of an ankle fracture
Study NCT04830605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based treatment
Description: The intervention is an internet-based psychotherapy treatment with eight modules based on acceptance and commitment therapy and with written therapist contact through eight weeks.
Study NCT05666687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIJ821
Description: MIJ821 will be administered as an i.v. infusion
Study NCT06207370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafenoquine
Description: Oral Tafenoquine
Study NCT06207370 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05072522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028
Description: SKLB1028 capsules, oral, once daily in continuous 28-day cycles
Study NCT05844761 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Triggered imaging on TrueBeam with margin reduction
Description: At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the TrueBeam triggered imaging motion management technique.
Study NCT05844761 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Synchrony MLC tracking on fiducials with margin reduction
Description: At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the Radixact Synchrony motion management technique.
Study NCT05844761 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Synchrony MLC tracking and lung adaptive model with margin reduction
Description: At interim analysis the Planning target volume (PTV) will be reduced based on the accuracy of the Radixact Synchrony motion management technique for lung cancer.
Study NCT05424445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Women presenting at the study site with an indication for IOL will receive written and oral information about the study. They will have the opportunity to ask questions. If the woman agrees to participate and is deemed eligible, she will sign informed consent. The Swedish national guidelines regarding the method of IOL will be followed. Women will have an abdominal palpation to exclude malpresentation, a CTG, and a digital cervical exam to establish bishop score (BS) prior to inclusion (as per clinical practice). Randomization will be performed by the attending physician, midwife or study coordinator. Randomization will be by opening numbered opaque sealed envelopes in sequential order containing the randomization code. There are no restrictions for use of other medications. All concomitant medication will be recorded in the CRF.
Study NCT05424445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Women presenting at the study site with an indication for IOL will receive written and oral information about the study. They will have the opportunity to ask questions. If the woman agrees to participate and is deemed eligible, she will sign informed consent. The Swedish national guidelines regarding the method of IOL will be followed. Women will have an abdominal palpation to exclude malpresentation, a CTG, and a digital cervical exam to establish bishop score (BS) prior to inclusion (as per clinical practice). Randomization will be performed by the attending physician, midwife or study coordinator. Randomization will be by opening numbered opaque sealed envelopes in sequential order containing the randomization code. There are no restrictions for use of other medications. All concomitant medication will be recorded in the CRF.
Study NCT06488794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colistimethate sodium
Description: 30 000 IU/kg of colistimethate sodium (equivalent to 0.96 mg/kg of colistin base) ,maximum 750000 IU, will be nebulized daily, divided into two doses for 3 days for eligible ventilated children starting from day 3 of mechanical ventilation.
Study NCT06488794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Nebulization of 3 ml of 0.9% saline twice a day for 3 days from day 3 of invasive mechanical ventilation for eligibile ventilated children
Study NCT05230979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Common bean baked snack
Description: Participants with normal weight (n=18) and with overweight (n=18) will attend the institute after 10-14 h fasting. Initially, they are going to complete a physical activity questionnaire, and the first visual analog scale (VAS) of subjective satiety questionnaire followed by a finger-prick blood sample. Immediately, they will be instructed to consume 40 g of the preload (common bean baked snack, cooked beans or white bread) along with 100 mL of water within 10 min. The VAS and blood glucose will be measured every 15 min after starting to eat the test food. Another VAS will be used to assess the palatability of the preload products. After 45 min, an ad libitum meal consisting of freshly prepared sandwiches and 250 mL of water will be served in a single portion. Finally, the VAS of subjective satiety is going to be assessed again.